Urelumab
Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD137 |
Clinical data | |
Other names | BMS-663513 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6502H9972N1712O2030S44 |
Molar mass | 146015.89 g·mol−1 |
(what is this?) (verify) |
Urelumab targets the extracellular domain of CD137.[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[3]
The first phase I trial began in 2006 and final results were published in 2015.[4]
Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.[2]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
- Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–20. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
- "Urelumab". National Cancer Institute.
- Clinical trial number NCT00309023 for "Study of BMS-663513 in Patients With Advanced Cancer" at ClinicalTrials.gov